Revolution Medicines, Inc. Overview
Pro stress-test →Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, with a pipeline comprising RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company represents a high-stakes precision oncology play focused on addressing one of oncology's most prevalent and difficult-to-treat driver mutations.
Strategic Profile
Pro stress-test →The company's lead drug, Daraxonrasib (RMC-6236), is now in global Phase 3 trials and recently secured a Commissioner's National Priority Voucher from the FDA in October 2025. Revolution Medicines is differentiated by its proprietary RAS(ON) inhibitor platform targeting previously undruggable RAS mutations, positioning it as a potential first-to-market player in a large oncology opportunity.
Competitive Landscape
Pro stress-test →Revolution Medicines competes in the precision oncology and RAS-targeted therapy space against larger pharmaceutical companies and specialized biotech firms developing RAS inhibitors. Key competitors include Amgen, Mirati Therapeutics (acquired by Takeda), and emerging competitors in the RAS mutation space. Revolution's differentiation lies in its multi-selective RAS(ON) platform targeting difficult-to-drug RAS variants.
Industry Context
Revolution Medicines, Inc. operates in Precision Oncology / Targeted Therapeutics.
Key facts
Founded: 2014 · Headquarters: Redwood City, California · Employees: 809 · Market cap: $13.7B